Advertisement
Skip to Content
Morningstar

I-MAB ADR IMAB Stock Quote

Morningstar Rating
| Rating as of

NASDAQ: IMAB

Last close prices updated as of Jan 27, 2023, 10:32 AM EST | USD | BATS BZX Real-Time Price
  • Last Close 6.41
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style
  • Day Range 6.34  –  6.84
  • Year Range 3.19  –  29.60
  • Market Cap 567.1579 Mil
  • Volume / Avg 109,588.0 /  515,766.7
  • Price / Sales 28.61
  • Price / Book 0.90
  • Forward Div Yield —
  • Trailing Div Yield —

Morningstar‘s Stock Analysis IMAB

Valuation
Currency in —
Is it the right time to buy or sell?
Find out with Morningstar Investor
Is it the right time to buy or sell?
Find out with Morningstar Investor

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

I-Mab Faces Uncertainty in Its Global Pipeline

Jay Lee Senior Equity Analyst

Business Strategy and Outlook

| Jay Lee |

I-Mab Biopharma is a clinical-stage Chinese biotech firm with strong innovative products in its pipeline. Its first commercial drug will be felzartamab (CD38, Greater China), which could be launched in China at the end of 2023 or early 2024 for third-line multiple myeloma, or MM. Other core assets are lemzoparlimab (“lemzo”, CD47, Greater China), uliledlimab ("uli," CD73, global rights), and eftansomatropin (long-acting growth hormone, Greater China). Although we do not award I-Mab a moat due to the early stage of its portfolio, we are impressed with its differentiation and rational design and believe it has a positive moat trend.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics IMAB

More

Company Profile IMAB

Business Description

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in late 2023 or early 2024. Core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature.

Contact
555 West Haiyang Road, 55th - 56th Floor, New Bund Center, Pudong District
Shanghai, 200124, CHN
Sector Healthcare
Industry Biotechnology
Employees 378

Related Articles IMAB

Market Update

Market Brief: Will the December CPI Report Help Further Tame Inflation Fears?

Jobs data reassures investors; declining natural gas prices hits energy stocks.
Lauren Solberg
Market Update

Morningstar’s Best- and Worst-Performing Stocks: 2022

Chinese stocks rebound, energy stocks such as Occidental surge, while Farfetch and other internet retailers plunge.
Jakir Hossain
Market Update

10 of the Cheapest Stocks of 2022

One silver lining of the bear market is half the stocks followed by Morningstar analysts are now undervalued.
Jakir Hossain
Market Update

The Best- and Worst-Performing Stocks: Q3 2022

Solar stocks shine, and retail remains buoyant. Chinese tech names and European healthcare get battered.
Jakir Hossain
Market Update

Markets Brief: Stocks Fall for the First Time in a Month, More Retail Earnings Ahead

Cheniere Energy Partners, Coterra Energy rally on higher gas prices. Bed Bath & Beyond shares plunge following volatile trading sessions.
Jakir Hossain
Market Update

Markets Brief: As Stocks Hold Recent Gains, CPI Report Ahead Could Set the Tone for the Fed

Oil stocks fall as crude oil prices decline. Uber and Lyft rally on solid earnings results.
Jakir Hossain
Market Update

Markets Brief: Are We Headed for an Earnings Recession?

Despite rising worries of recession and a bear market, stock analysts have become more optimistic. That could be a risk for investors.
Sandy Ward
Market Update

Markets Brief: How High Can Mortgage Rates Go?

Existing home sales figures from May are on deck. Energy stocks lose juice, while Chinese ADRs continue to rally.
Sandy Ward

Related News IMAB

More

FAQs for I-MAB ADR Stock

No. IMAB does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

IMAB’s market cap is 567.16 Mil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

IMAB’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare IMAB’s historical performance against its industry peers and the overall market.